Brittany Duke, Pharm D R Ph
About Brittany Duke, Pharm D R Ph
Brittany Duke, Pharm D, R Ph, is the Manager of Global Regulatory Affairs at Bristol Myers Squibb and the Pharmacy Director/Owner at Rx Care Consulting, with extensive experience in regulatory affairs, clinical research, and pharmacy practice.
Current Title and Company
Brittany Duke currently holds the title of Manager Global Regulatory Affairs at Bristol Myers Squibb. In this role, she is responsible for driving operational excellence in Global Regulatory Strategy & Policy. Her tasks include supporting regulatory lead preparations for health authority interactions, maintaining tracking data for key regulatory milestones, and coordinating global regulatory subteam meetings.
Pharmacy Director/Owner at Rx Care Consulting
In addition to her role at Bristol Myers Squibb, Brittany Duke also serves as Pharmacy Director and Owner of Rx Care Consulting based in the Washington DC-Baltimore Area. This dual role underscores her multifaceted expertise in the field of pharmacy and regulatory affairs.
Previous Experience at Brillient Corporation
Brittany Duke has previously worked at Brillient Corporation as a Subject Matter Expert III- Medical Writer/Analyst IV. During her 11-month tenure from 2020 to 2021 in Silver Spring, Maryland, she assumed responsibilities related to FDA|CDER|OSE|OMEPRM|DMEPA|RRT, showcasing her expertise in medical writing and regulatory analysis.
Educational Background
Brittany Duke obtained her Doctor of Pharmacy (PharmD) from the University of Maryland Eastern Shore, where she studied from 2011 to 2014. She also holds a Bachelor of Science (BS) degree in Microbiology from the University of Maryland College Park, which she completed between 2004 and 2008. Her academic background lays a solid foundation for her extensive career in pharmacy and regulatory affairs.
Experience with FDA and Regulatory Roles
Brittany Duke has accumulated significant experience in various roles tied to the FDA. She has served as an ORISE Post-Doctoral Fellow in multiple offices, including the Office of New Drugs and the Office of Surveillance and Epidemiology, contributing to pharmacovigilance and drug evaluation. She has also worked as a Pharmacist II at Chenega Professional Services Strategic Business Unit and as a subject matter expert at Brillient Corporation, highlighting her broad expertise in federal regulatory environments.